PE20121639A1 - Derivados de 3-hidroxi-5-arilizotiazol como moduladores de gpr40 - Google Patents

Derivados de 3-hidroxi-5-arilizotiazol como moduladores de gpr40

Info

Publication number
PE20121639A1
PE20121639A1 PE2012000884A PE2012000884A PE20121639A1 PE 20121639 A1 PE20121639 A1 PE 20121639A1 PE 2012000884 A PE2012000884 A PE 2012000884A PE 2012000884 A PE2012000884 A PE 2012000884A PE 20121639 A1 PE20121639 A1 PE 20121639A1
Authority
PE
Peru
Prior art keywords
alkyl
arylizothiazole
gpr40
hydroxy
halogen
Prior art date
Application number
PE2012000884A
Other languages
English (en)
Inventor
Akihiro Okano
Naoto Kosuga
Munetaka Ohkouchi
Daido Hotta
Muneyoshi Makabe
Original Assignee
Mochida Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mochida Pharm Co Ltd filed Critical Mochida Pharm Co Ltd
Publication of PE20121639A1 publication Critical patent/PE20121639A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • C07D275/03—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

REFERIDA A UN DERIVADO DE 3-HIDROXI-5-ARILIZOTIAZOL DE FORMULA (I), DONDE n Y k SON UN ENTERO DE 0 A 2; p ES UN ENTERO DE 0 A 4; j ES UN ENTERO DE 0 A 3; EL ANILLO A ES UN GRUPO ARILO C6-C14 O UN HETEROCICLO DE 3 A 14 MIEMBROS, OPCIONALMENTE SUSTITUIDOS CON L; EL ANILLO B ES BENCENO, PIRIDINA O PIRIMIDINA; X ES O, S, NR7; R1 ES HALOGENO, ALQUILO C1-C6, ALQUENILO C2-C6, ENTRE OTROS; R2 ES H, HALOGENO, ALQUILO C1-C6, ENTRE OTROS; R3, R4, R5, R6 Y R7 SON H, ALQUILO C1-C6, ALQUENILO C2-C6, ENTRE OTROS; L ES HALOGENO, OH, CN, ALQUILO C1-C10, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS MODULAN LA FUNCION DEL RECEPTOR 40 ACOPLADO A LA PROTEINA G (GPR40) Y SON UTILES EN EL TRATAMIENTO DE TRASTORNOS TALES COMO LA DIABETES
PE2012000884A 2009-12-25 2010-12-24 Derivados de 3-hidroxi-5-arilizotiazol como moduladores de gpr40 PE20121639A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009295855 2009-12-25
JP2010043420 2010-02-26

Publications (1)

Publication Number Publication Date
PE20121639A1 true PE20121639A1 (es) 2012-12-02

Family

ID=44195895

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2012000884A PE20121639A1 (es) 2009-12-25 2010-12-24 Derivados de 3-hidroxi-5-arilizotiazol como moduladores de gpr40

Country Status (26)

Country Link
US (1) US8476287B2 (es)
EP (1) EP2518060A4 (es)
JP (2) JP5002077B2 (es)
KR (1) KR20130004262A (es)
CN (2) CN104710381A (es)
AU (1) AU2010336225A1 (es)
BR (1) BR112012015612A2 (es)
CA (1) CA2785674A1 (es)
CL (1) CL2012001722A1 (es)
CO (1) CO6650337A2 (es)
CR (1) CR20120345A (es)
EA (1) EA201290574A1 (es)
EC (1) ECSP12012056A (es)
GT (1) GT201200217A (es)
HN (1) HN2012001351A (es)
IL (1) IL220616A0 (es)
MA (1) MA33952B1 (es)
MX (1) MX2012007474A (es)
NI (1) NI201200113A (es)
NZ (1) NZ601408A (es)
PE (1) PE20121639A1 (es)
PH (1) PH12012501456A1 (es)
RU (1) RU2567755C2 (es)
SG (1) SG181961A1 (es)
WO (1) WO2011078371A1 (es)
ZA (1) ZA201203416B (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2011052756A1 (ja) 2009-10-30 2013-03-21 持田製薬株式会社 新規３−ヒドロキシ−５−アリールイソキサゾール誘導体
NZ601408A (en) 2009-12-25 2013-12-20 Mochida Pharm Co Ltd Novel 3-hydroxy-5-arylisothiazole derivative
US8581584B2 (en) * 2010-05-26 2013-11-12 Florida State University Research Foundation Membrane proteins, mechanisms of action and uses thereof
JP5809157B2 (ja) 2010-10-08 2015-11-10 持田製薬株式会社 環状アミド誘導体
BR112013021236B1 (pt) 2011-02-25 2021-05-25 Merck Sharp & Dohme Corp composto derivado de benzimidazol, e, composição
BR112013027883A2 (pt) * 2011-04-27 2017-08-08 Mochida Pharm Co Ltd novo derivado de 1-óxido de 3-hidroxiisotiazol
AU2012248627A1 (en) * 2011-04-28 2013-11-14 Mochida Pharmaceutical Co., Ltd. Cyclic amide derivative
WO2013154163A1 (ja) * 2012-04-11 2013-10-17 持田製薬株式会社 新規５－アリール－１，２－チアジナン誘導体
JP6378171B2 (ja) 2012-04-24 2018-08-22 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ｄｎａ−ｐｋ阻害剤
CA2878625A1 (en) 2012-07-11 2014-01-16 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
US9527875B2 (en) 2012-08-02 2016-12-27 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
RU2015140066A (ru) 2013-02-22 2017-03-30 Мерк Шарп И Доум Корп. Противодиабетические бициклические соединения
SI3527563T1 (sl) 2013-03-12 2022-01-31 Vertex Pharmaceuticals Incorporated Inhibitorji DNA-PK
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
RU2675270C2 (ru) 2013-10-17 2018-12-18 Вертекс Фармасьютикалз Инкорпорейтед Сокристаллы и содержащие их фармацевтические композиции
IN2013MU03577A (es) 2013-11-14 2015-07-31 Cadila Healthcare Ltd
RU2701188C2 (ru) * 2015-02-27 2019-09-25 Нэнтбайосайенс, Инк. Производные пиримидина в качестве ингибиторов киназы и их терапевтические применения
JP6616244B2 (ja) * 2015-05-29 2019-12-04 北興化学工業株式会社 新規なヒドロキシフェニルボロン酸エステルとその製造方法、およびヒドロキシビフェニル化合物の製造法
RU2758669C2 (ru) 2016-09-27 2021-11-01 Вертекс Фармасьютикалз Инкорпорейтед Способ лечения рака с применением сочетания днк-поражающих агентов и ингибиторов днк-пк
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
BR102018007822A2 (pt) 2017-04-20 2018-11-06 Gilead Sciences, Inc. composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
TWI707849B (zh) 2018-02-13 2020-10-21 美商基利科學股份有限公司 Pd‐1/pd‐l1抑制劑
KR102591947B1 (ko) 2018-04-19 2023-10-25 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
EP3820572B1 (en) 2018-07-13 2023-08-16 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
US11236085B2 (en) 2018-10-24 2022-02-01 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
CN110066254B (zh) * 2018-11-16 2021-03-19 温州大学 一种异噻唑-3-酮化合物的制备方法
JP2022552655A (ja) 2019-10-07 2022-12-19 キャリーオペ，インク． Ｇｐｒ１１９アゴニスト
IL295825A (en) 2020-02-28 2022-10-01 Kallyope Inc gpr40 agonists
WO2021236617A1 (en) 2020-05-19 2021-11-25 Kallyope, Inc. Ampk activators
CA3183575A1 (en) 2020-06-26 2021-12-30 Iyassu Sebhat Ampk activators
CN115433143B (zh) * 2021-06-03 2023-10-13 中国科学院大连化学物理研究所 一种异噻唑啉酮类化合物的合成方法
CN115386028B (zh) * 2022-08-26 2023-06-23 长春理工大学 一种聚合度可控的聚山梨酸-d-薄荷醇酯及合成方法与应用
CN117510431A (zh) * 2023-11-08 2024-02-06 浙江雅辰药物科技股份有限公司 一种异噻唑-3-酮及其衍生物、合成方法
WO2025140655A1 (en) * 2023-12-30 2025-07-03 Fujian Haixi Pharmaceuticals Co., Ltd. Heteroaryl compounds as multi-target protein kinase inhibitors

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3562283A (en) 1968-07-01 1971-02-09 Rohm & Haas 1-oxo and 1,1-dioxo-3-isothiazolones
US3801575A (en) * 1972-01-24 1974-04-02 Rohm & Haas 3-hydroxyisothiazoles
RU2165415C2 (ru) 1996-02-27 2001-04-20 Санкио Компани Лимитед Производные изоксазола и фармацевтическая композиция на их основе
HUP0105092A3 (en) 1999-01-13 2003-12-29 Warner Lambert Co 1-heterocycle substituted diarylamines and medicaments containing them
JP2000204077A (ja) 1999-01-13 2000-07-25 Warner Lambert Co ジアリ―ルアミン
WO2004011446A1 (en) 2002-07-26 2004-02-05 Bayer Pharmaceuticals Corporation Indane, dihydrobenzofuran, and tetrahydronaphthalene carboxylic acid derivatives and their use as antidiabetics
AU2003261935A1 (en) 2002-09-06 2004-03-29 Takeda Pharmaceutical Company Limited Furan or thiophene derivative and medicinal use thereof
AU2003277576A1 (en) 2002-11-08 2004-06-07 Takeda Pharmaceutical Company Limited Receptor function controlling agent
JP4594611B2 (ja) * 2002-11-08 2010-12-08 武田薬品工業株式会社 受容体機能調節剤
EP1630152A4 (en) 2003-05-30 2009-09-23 Takeda Pharmaceutical CONDENSED CYCLIC COMPOUND
US7141596B2 (en) 2003-10-08 2006-11-28 Incyte Corporation Inhibitors of proteins that bind phosphorylated molecules
WO2005051890A1 (en) 2003-11-19 2005-06-09 Smithkline Beecham Corporation Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to gpr40
AU2004309271A1 (en) 2003-12-25 2005-07-14 Takeda Pharmaceutical Company Limited 3-(4-benzyloxyphenyl)propanoic acid derivatives
JP5299810B2 (ja) 2004-02-27 2013-09-25 アムジエン・インコーポレーテツド 代謝疾患の治療に使用するための、化合物、薬学的組成物及び方法
SE0500055D0 (sv) * 2005-01-10 2005-01-10 Astrazeneca Ab Therapeutic agents 3
KR20080033524A (ko) 2005-08-10 2008-04-16 다케다 야쿠힌 고교 가부시키가이샤 당뇨병 치료제
WO2007033002A1 (en) 2005-09-14 2007-03-22 Amgen Inc. Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders
TW200815377A (en) 2006-04-24 2008-04-01 Astellas Pharma Inc Oxadiazolidinedione compound
BRPI0713378A8 (pt) 2006-06-27 2018-01-02 Takeda Pharmaceutical composto, pró-droga, modulador da função do receptor gpr40, agente farmacêutico uso do composto, e, método de produção de uma forma opticamente ativa de um composto
CA2662305C (en) 2006-09-07 2012-04-17 Amgen Inc. Heterocyclic gpr40 modulators
WO2008033931A1 (en) 2006-09-13 2008-03-20 The Institutes For Pharmaceutical Discovery, Llc Para-xylylene carboxylic acids and isothiazolones useful as protein tyrosine phosphatases (ptps) in particular ptp-ib
EP2098517B1 (en) 2006-12-01 2013-12-18 Msd K.K. Novel phenyl-isoxazol-3-ol derivative
EP2139843B1 (en) 2007-04-16 2013-12-25 Amgen, Inc Substituted biphenyl phenoxy-, thiophenyl- and aminophenylpropanoic acid gpr40 modulators
EP2203416B1 (de) 2007-09-21 2016-10-26 Sanofi (carboxylalkylen-phenyl)-phenyl-oxalamide, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
CN102083783A (zh) 2007-10-10 2011-06-01 安姆根有限公司 取代的联苯gpr40调节剂
JP2011016722A (ja) 2007-10-23 2011-01-27 Astellas Pharma Inc チアゾリジンジオン化合物
TW200932219A (en) 2007-10-24 2009-08-01 Astellas Pharma Inc Oxadiazolidinedione compound
US8299296B2 (en) 2007-10-26 2012-10-30 Japan Tobacco Inc. Spiro compounds and pharmaceutical use thereof
WO2009111056A1 (en) 2008-03-06 2009-09-11 Amgen Inc. Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders
WO2009147990A1 (ja) * 2008-06-02 2009-12-10 萬有製薬株式会社 新規イソオキサゾール誘導体
NZ588983A (en) 2008-06-25 2011-11-25 Daiichi Sankyo Co Ltd Carboxylic acid compound
WO2010085525A1 (en) 2009-01-23 2010-07-29 Schering Corporation Bridged and fused heterocyclic antidiabetic compounds
AR075051A1 (es) 2009-02-05 2011-03-02 Schering Corp Compuestos antidiabeticos que contienen ftalazina
WO2010143733A1 (en) 2009-06-09 2010-12-16 Takeda Pharmaceutical Company Limited Novel fused cyclic compound and use thereof
AR078522A1 (es) 2009-10-15 2011-11-16 Lilly Co Eli Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis
JPWO2011052756A1 (ja) 2009-10-30 2013-03-21 持田製薬株式会社 新規３−ヒドロキシ−５−アリールイソキサゾール誘導体
AR078948A1 (es) 2009-11-30 2011-12-14 Lilly Co Eli Compuestos de espiropiperidina, composicion farmaceutica que lo comprenden y su uso para preparar un medicamento util para tratar la diabetes
NZ601408A (en) 2009-12-25 2013-12-20 Mochida Pharm Co Ltd Novel 3-hydroxy-5-arylisothiazole derivative
CN101781268B (zh) * 2010-02-25 2012-05-30 中国人民解放军军事医学科学院毒物药物研究所 异噻唑酮取代的苯二羧酸衍生物及其用于制备β-分泌酶抑制剂的用途
JP5809157B2 (ja) 2010-10-08 2015-11-10 持田製薬株式会社 環状アミド誘導体

Also Published As

Publication number Publication date
ZA201203416B (en) 2013-08-28
JP2012153726A (ja) 2012-08-16
CL2012001722A1 (es) 2012-12-14
KR20130004262A (ko) 2013-01-09
US20120157459A1 (en) 2012-06-21
SG181961A1 (en) 2012-08-30
CN104710381A (zh) 2015-06-17
CN102712610B (zh) 2015-03-04
MA33952B1 (fr) 2013-01-02
EA201290574A1 (ru) 2012-12-28
IL220616A0 (en) 2012-08-30
PH12012501456A1 (en) 2012-10-29
CO6650337A2 (es) 2013-04-15
EP2518060A1 (en) 2012-10-31
NI201200113A (es) 2012-08-13
MX2012007474A (es) 2012-08-01
US8476287B2 (en) 2013-07-02
CR20120345A (es) 2012-11-01
RU2567755C2 (ru) 2015-11-10
JP5002077B2 (ja) 2012-08-15
BR112012015612A2 (pt) 2016-03-15
HN2012001351A (es) 2015-03-23
NZ601408A (en) 2013-12-20
RU2012131840A (ru) 2014-01-27
ECSP12012056A (es) 2012-10-30
EP2518060A4 (en) 2014-01-08
CN102712610A (zh) 2012-10-03
AU2010336225A1 (en) 2012-08-16
CA2785674A1 (en) 2011-06-30
WO2011078371A1 (ja) 2011-06-30
JPWO2011078371A1 (ja) 2013-05-09
GT201200217A (es) 2014-02-10

Similar Documents

Publication Publication Date Title
PE20121639A1 (es) Derivados de 3-hidroxi-5-arilizotiazol como moduladores de gpr40
EA201390947A1 (ru) Соединения 2-амино-4-арилтиазола в качестве антагонистов trpa1
PE20191495A1 (es) Piridonamidas como moduladores de canales de sodio
EA201290774A1 (ru) Пиразолопиридиновые, пиразолопиразиновые, пиразолопиримидиновые, пиразолотиофеновые и пиразолотиазоловые соединения как аллостерические потенциаторы mglur4, композиции и способы лечения неврологических дисфункций
CY1114718T1 (el) ΠΑΡΑΓΩΓΑ 1,2,4-ΤΡΙΑΖΟΛΟ[4,3-a]ΠΥΡΙΔΙΝΗΣ ΚΑΙ ΧΡΗΣΗ ΑΥΤΩΝ ΓΙΑ ΤΗ ΘΕΡΑΠΕΙΑ Ή ΤΗΝ ΠΡΟΛΗΨΗ ΝΕΥΡΟΛΟΓΙΚΩΝ ΚΑΙ ΨΥΧΙΑΤΡΙΚΩΝ ΔΙΑΤΑΡΑΧΩΝ
EA200971143A1 (ru) Бензамидные mglur5 позитивные аллостерические модуляторы и способы их получения и применения
DOP2013000181A (es) Moduladores del receptor de glucagon
EA200870196A1 (ru) Индолсульфонамидные модуляторы рецепторов прогестерона
PE20110028A1 (es) Derivados de isoxazol y su uso como potenciadores de los receptores metabotropicos de glutamato
UY32888A (es) Dihidrobenzocicloalquiloximetil-oxazolopirimidinonas sustituidas, preparación y uso de las mismas
MX2011005242A (es) Derivados de indol y benzoxazina como moduladores de los receptores de glutamato metabotropicos.
PE20090158A1 (es) Dihidro y tetrahidro oxazolopirimidinonas sustituidas y preparaciones de las mismas
PE20091734A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
EA200870197A1 (ru) Новые 2-замещённые бензимидазолы в качестве селективных модуляторов рецептора андрогена (sarms)
EA201190138A1 (ru) Производные фуропиримидиндиона в качестве модуляторов trpa1
PE20141211A1 (es) Moduladores receptores de hormonas nucleares
EA201170198A1 (ru) Фармацевтические композиции, содержащие лиганды рецептора дофамина
PE20120561A1 (es) Compuestos que modulan selectivamente el receptor cb2
EP2490537A4 (en) ALLOSTERIC MGLUR4 POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTIONS
PE20160589A1 (es) Heteroaril-ciclohexil-tetraazabenzo[e]azulenos como antagonistas de los receptores de vasopresina v1a
PE20130401A1 (es) Heteroaril-ciclohexil-tetraazabenzo[e]azulenos
CL2009000116A1 (es) Compuestos derivados de heterotriciclos sustituidos, antagonistas del receptor crf; sus composiciones farmaceuticas; y uso de dichos compuestos para el tratamiento de trastornos afectivos, depresion, ansiedad y sindrome del colon irritable.
CO6321281A2 (es) Derivados de tetrazol como moduladores de receptores de glutamato metabotropicos (mglurs)
CY1119449T1 (el) Ενωσεις 1,2,4-τριαζολο|4,3-α]πυριδινης και η χρηση αυτων ως θετικων αλλοστερiκων ρυθμιστων των υποδοχεων mglur2
CO6541592A2 (es) Tiazoles biciclicos como moduladores alostericos de receptores de mglur5

Legal Events

Date Code Title Description
FA Abandonment or withdrawal